Clinuvel Pharmaceuticals Limited (FRA:UR9)

Clinuvel Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is July - June.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 29, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Capitalization	325	290	479	539	484	959
Market Cap Growth	-9.28%	-39.41%	-11.00%	11.37%	-49.58%	23.36%
Enterprise Value	193	180	371	454	419	914
Last Close Price	6.50	5.73	9.24	10.84	9.70	18.94
PE Ratio	16.10	14.38	21.60	28.87	35.14	61.34
PS Ratio	6.13	5.48	8.73	11.28	11.16	31.39
PB Ratio	2.42	2.16	3.79	5.37	5.84	15.36
P/TBV Ratio	2.42	2.16	3.80	5.37	5.85	15.39
P/FCF Ratio	14.27	12.75	24.46	24.62	18.61	82.41
P/OCF Ratio	14.17	12.66	20.77	23.93	18.40	78.75
EV/Sales Ratio	3.46	3.40	6.76	9.50	9.68	29.91
EV/EBITDA Ratio	7.01	6.94	12.09	16.71	17.68	49.73
EV/EBIT Ratio	7.18	7.05	12.28	16.86	17.89	50.60
EV/FCF Ratio	8.49	7.91	18.95	20.73	16.13	78.52
Debt / Equity Ratio	0.00	0.00	0.00	0.01	0.01	0.01
Debt / EBITDA Ratio	0.01	0.01	0.02	0.02	0.03	0.04
Debt / FCF Ratio	0.01	0.01	0.03	0.03	0.03	0.07
Asset Turnover	0.38	0.38	0.42	0.46	0.52	0.51
Inventory Turnover	0.87	0.87	0.77	1.33	3.69	1.87
Quick Ratio	9.24	9.24	8.33	7.02	10.03	11.35
Current Ratio	9.66	9.66	8.81	7.44	10.24	11.81
Return on Equity (ROE)	16.30%	16.30%	19.39%	21.09%	18.62%	28.95%
Return on Assets (ROA)	11.37%	11.37%	14.29%	16.34%	17.60%	18.78%
Return on Invested Capital (ROIC)	186.33%	172.36%	236.84%	419.57%	190.89%	229.04%
Return on Capital Employed (ROCE)	18.70%	18.70%	23.60%	26.20%	27.30%	28.60%
Earnings Yield	6.21%	6.95%	4.63%	3.46%	2.84%	1.63%
FCF Yield	7.01%	7.84%	4.09%	4.06%	5.38%	1.21%
Dividend Yield	0.40%	0.49%	0.34%	0.28%	0.27%	0.08%
Payout Ratio	6.92%	6.92%	6.93%	6.46%	5.92%	5.00%
Buyback Yield / Dilution	1.27%	1.27%	1.52%	-0.08%	-1.26%	-1.33%
Total Shareholder Return	1.67%	1.75%	1.86%	0.21%	-0.99%	-1.25%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.